Skip to main content
Writing the Talking Cure

Writing the Talking Cure

By Berman, Jeffrey

Published by State University of New York Press

English 2019
eBook

About this book

Explores Yalom's profound contributions to psychotherapy and literature. A distinguished psychiatrist and psychotherapist, Irvin D. Yalom is also the United States' most well-known author of psychotherapy tales. His first volume of essays, Love's Executioner, became an immediate best seller, and his first novel, When Nietzsche Wept, continues to enjoy critical and popular success. Yalom has created a subgenre of literature, the "therapy story," where the therapist learns as much as, if not more than, the patient; where therapy never proceeds as expected; and where the therapist's apparent failure provesultimately to be a success. Writing the Talking Cure is the first book to explore all of Yalom's major writings. Taking an interdisciplinary approach, Jeffrey Berman comments on Yalom's profound contributions to psychotherapy and literature and emphasizes the recurrent ideas that unify his writings: the importance of the therapeutic relationship, therapist transparency, here-and-now therapy, the prevalence of death anxiety, reciprocal healing, and the idea of the wounded healer. Throughout, Berman discusses what Yalom can teach therapists in particular and the common (and uncommon) reader in general.

Availability

Writing the Talking Cure is available as eBook at 9 online bookshops. Bookshops carrying it include Bajalibros Argentina, Bajalibros Latam, Bookshop Uruguay.

Language
English
Share

Frequently asked questions

In what formats is Writing the Talking Cure available?
Writing the Talking Cure is available as eBook at 9 online bookshops.
Where can I buy Writing the Talking Cure?
You can buy Writing the Talking Cure at Bajalibros Argentina, Bajalibros Latam, Bookshop Uruguay. Compare every option in the list on this page.

Ratings & reviews

No ratings yet. Be the first to review this book.

Sign in to rate and review this book.

Comments

Sign in to join the conversation.

No comments yet.